T1	Participants 56 110	patients after hematopoietic stem cell transplantation
T2	Participants 314 421	One hundred fifty-seven patients were screened for cognitive deficits following HSCT for malignant diseases
T3	Participants 472 511	Patients showing evidence of impairment